227 related articles for article (PubMed ID: 8424417)
21. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
Roemer K
Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
[TBL] [Abstract][Full Text] [Related]
22. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
23. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
King TC; Estalilla OC; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
[TBL] [Abstract][Full Text] [Related]
24. The p53 gene and its role in human brain tumors.
Bögler O; Huang HJ; Kleihues P; Cavenee WK
Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene.
Yamada K; Zhong X; Kanazawa S; Koike J; Tsujita K; Hemmi H
Oncol Rep; 2003; 10(4):859-66. PubMed ID: 12792735
[TBL] [Abstract][Full Text] [Related]
26. p53 loss of function: implications for the processes of immortalization and tumorigenesis.
Finlay CA
Bioessays; 1992 Aug; 14(8):557-60. PubMed ID: 1365909
[TBL] [Abstract][Full Text] [Related]
27. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
28. [Environmental carcinogens and p53 gene mutation].
Xu Z; Jin Y
Wei Sheng Yan Jiu; 2004 Mar; 33(2):239-43. PubMed ID: 15209018
[TBL] [Abstract][Full Text] [Related]
29. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
30. p53: prospects for cancer gene therapy.
Soddu S; Sacchi A
Cytokines Cell Mol Ther; 1998 Sep; 4(3):177-85. PubMed ID: 9825843
[TBL] [Abstract][Full Text] [Related]
31. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis.
Soussi T; Dehouche K; Béroud C
Hum Mutat; 2000; 15(1):105-13. PubMed ID: 10612830
[TBL] [Abstract][Full Text] [Related]
32. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
[TBL] [Abstract][Full Text] [Related]
33. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
Srinivasan R; Maxwell SA
Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
[TBL] [Abstract][Full Text] [Related]
34. Neoplastic transformation of human cells in vitro.
Rhim JS
Crit Rev Oncog; 1993; 4(3):313-35. PubMed ID: 8485202
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of wild-type p53 and c-Myc in human fetal cells transformed with adenovirus early region 1.
Grand RJ; Lecane PS; Roberts S; Grant ML; Lane DP; Young LS; Dawson CW; Gallimore PH
Virology; 1993 Apr; 193(2):579-91. PubMed ID: 8460477
[TBL] [Abstract][Full Text] [Related]
36. Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53.
Montenarh M
Crit Rev Oncog; 1992; 3(3):233-56. PubMed ID: 1616956
[TBL] [Abstract][Full Text] [Related]
37. The expression of p53 protein in salivary gland carcinomas.
Potencz E; Cornianu M; Muntean C; Sotiriadis S
Rom J Morphol Embryol; 1998; 44(1-4):109-15. PubMed ID: 15678851
[TBL] [Abstract][Full Text] [Related]
38. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
39. Adenomatous polyposis coli gene mutation and decreased wild-type p53 protein expression in oral submucous fibrosis: a preliminary investigation.
Liao PH; Lee TL; Yang LC; Yang SH; Chen SL; Chou MY
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):202-7. PubMed ID: 11505268
[TBL] [Abstract][Full Text] [Related]
40. p53: balancing tumour suppression and implications for the clinic.
Buganim Y; Rotter V
Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
